Key policy discussions from US biotech events in the last half of 2024 are shaping the industry's trajectory for 2025, focusing on regulatory frameworks, investment incentives, and ethical considerations.

AI is rapidly transforming early-stage biotech R&D, creating three crucial shifts for startups in the next year by accelerating drug discovery, enhancing precision medicine, and optimizing operational efficiency, ensuring competitive advantage.

The biotech workforce is rapidly evolving, demanding new skill sets; employers in Q1 2025 will prioritize seven essential competencies to drive innovation and meet industry challenges.

The 2025 biotech IPO landscape in the US presents compelling opportunities for discerning investors. Understanding market dynamics and identifying innovative companies are crucial for success in this high-growth sector.

Exploring 2025's top US biotech summits provides crucial insider knowledge into emerging market opportunities, offering strategic insights for investors and industry professionals navigating the dynamic biotech landscape.

For US biotech startups navigating 2025, robust intellectual property protection is paramount. This article outlines practical strategies to avoid common pitfalls, ensuring your innovations are safeguarded against infringement and competitive threats.